TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
TriSalus Life Sciences, Inc. (TLSI)
Company Research
Source: Business Wire
Reports $13.2 million in Revenue in the Fourth Quarter, $45.2 million for Full-Year of 2025, Representing increases of 60% and 53%, respectively, Versus the Prior Year PeriodsReaffirms 2026 Revenue Guidance of $60-62 millionStrengthened Balance Sheet with $46 Million Gross Proceeds from Recent Public OfferingHosting Conference Call and Webcast today at 4:30pm ET DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter and year ended December 31, 2025, and provides an operational update.“During our fourth quarter and throughout 2025, we continued to deliver strong commercial performance, supported by the growing clinical adoption of our TriNav® product suite and proprietary PEDD® platform across a broad range of solid tu
Show less
Read more
Impact Snapshot
Event Time:
TLSI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLSI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSI alerts
High impacting TriSalus Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
TLSI
News
- TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance [Yahoo! Finance]Yahoo! Finance
- TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference CallBusiness Wire
- TriSalus Life Sciences Announces Pricing of $40.0 Million Public OfferingBusiness Wire
- TriSalus Life Sciences Proposes Public OfferingBusiness Wire
TLSI
Earnings
- 3/5/26 - Miss
TLSI
Analyst Actions
- 12/17/25 - Canaccord Genuity
TLSI
Sec Filings
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- 2/26/26 - Form 424B5
- TLSI's page on the SEC website